Results 71 to 80 of about 101,088 (262)
Intravenous Immunoglobulin and its Complications
Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2011 Intravenous immunoglobulin (IVIG) is a safe biological product used in many cases, such as primary and secondary immune deficiency, infectious diseases, critically ill patients and autoimmune disorders.
I Mohammadzadeh
doaj
Brain and BehaviorBackground Autoimmune encephalitis is an immune‐mediated inflammatory condition affecting the central nervous system. Current best‐practice guidelines recommend intravenous immunoglobulin (IVIG) for use if corticosteroids are ineffective, but the ...
Anahat Kalra +4 more
doaj +1 more source
Pathogenic Role of FGFR3 Autoantibodies in Small Fiber Neuropathy
Advanced Science, EarlyView.Autoantibodies against fibroblast growth factor receptor 3 (FGFR3) are identified as pathogenic drivers of pain in small fiber neuropathy. By binding to sensory neurons in dorsal root ganglia, FGFR3 autoantibodies activate MAPK signaling and induce hyperexcitability and mechanical hypersensitivity, establishing FGFR3 autoantibodies as a therapeutic ...
Lyuba Y. Salih +12 more
wiley +1 more source
ADVERSE EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH ANTIBODY DEFICIENCY
Iranian Journal of Allergy, Asthma and Immunology, 2003 Long-term intravenous immunoglobulin (IVIG) infusion is an effective treatment for children with humoral immunodeficiencies, already be complicated by systemic ad¬verse effects.
A. Aghamohammadi +11 more
doaj
TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
Advanced Science, EarlyView.We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng +9 more
wiley +1 more source
Медична наука України, 2017 At hepatology intravenous immunoglobulin was tested in several areas, but the evidence base of effectiveness is different at each nosology and often insufficient for routine use of the drug.
D.V. Maltsev, D.P. Muzyca
doaj +1 more source
Advanced Science, EarlyView.Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao +14 more
wiley +1 more source
Advanced Science, EarlyView.T cell‐specific Socs1 knockout leads to inflammatory differentiation of CD8+ T cells, prompting the STAT1/2 complex to drive the activation of Ccl5, Ccr5, and Cxcr3, and promoting the skewing of monocytes toward a pro‐inflammatory M1 macrophage lineage.
Zhigui Wu +14 more
wiley +1 more source
Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy
Annals of Clinical and Translational NeurologyObjective Multifocal motor neuropathy is a rare chronic immune‐mediated neuropathy with impaired grip strength representing a common symptom. While intravenous immunoglobulin G is an effective treatment for the disease, significant variation in treatment
Zhaoyang Li +3 more
doaj +1 more source
In Situ Lipoprotein‐seeking Dye for in Vivo Real‐Time Imaging of Lipid Dysregulation Diseases
Advanced Science, EarlyView.This study develops lipoprotein‐seeking NIR‐II dyes that specifically bind circulating lipoproteins. These dyes form ultra‐stable complexes with endogenous lipoprotein, enabling real‐time, high‐contrast imaging of fatty liver and atherosclerotic plaques. Tunable binding kinetics allow customized imaging windows.
Yijing Du +6 more
wiley +1 more source